Abstract
Increasing evidence links circadian and sleep disruptions with depression, though whether they are causally related remains unclear. This study used Mendelian randomization (MR) with exposures instrumented using genome-wide genetic variants and data from the UK Biobank (n=408 480; mean age=56.9 years) to explore causal associations between circadian and sleep traits, and depression. We conducted bidirectional MR analyses between morningness, sleep duration, insomnia symptoms, and depression, and secondary unidirectional analyses with circadian and sleep traits as exposures and mixed anxiety-depressive symptoms and anxiety disorders as outcomes. Using inverse-variance weighting and sensitivity analyses for horizontal pleiotropy (MR-Egger and Weighted Median Estimator), we found suggestive associations between morningness and lower odds of depression (diagnosis and treatment: OR=0.89, 95%CI=0.80, 0.98), and depression and shorter sleep duration (β=-4.67 minutes, 95%CI=-7.44; -1.89). Depression showed an effect on insomnia (any symptoms: OR=1.22, 95%CI=1.11; 1.34; frequent symptoms: OR=1.30, 95%CI=1.19; 1.42), while frequent insomnia was associated with increased odds of depression (diagnosis: OR=1.14, 95%CI=1.10; 1.19; diagnosis and treatment: OR=1.10, 95%CI=1.06; 1.14). Insomnia also had an effect on mixed anxiety-depressive symptoms (any symptoms: OR=1.19, 95%CI=1.08, 1.32; frequent symptoms: OR=1.20, 95%CI=1.17, 1.23), but no associations were found between the exposures and anxiety disorders. These findings shed light on the causal links between the circadian system and depression.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
VP was supported by Programa de Desarrollo de las Ciencias Basicas (PEDECIBA, MEC-UdelaR, Uruguay), Agencia Nacional de Investigacion e Innovacion (ANII, Uruguay) [grant number MOV_CA_2020_1_163153], Comision Sectorial de Investigacion Cientifica (CSIC, UdelaR, Uruguay) and, Comision Academica de Posgrados (CAP, UdelaR, Uruguay). MR is funded by the UK Medical Research Council (grants MC_UU_00019/1 and 3). BT and AS were supported by Comision Sectorial de Investigacion Cientifica (CSIC, UdelaR, Uruguay) [grant number 883158]. VG was supported by the Professor David Matthews Non-Clinical Fellowship from the Diabetes Research and Wellness Foundation (United Kingdom) [grant number SCA/01/NCF/22].
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for this work was granted by the North West Haydock Research Ethics Committee of the Health Research Authority from UK.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The UK Biobank data are publicly available to all bona fide researchers at https://www.ukbiobank.ac.uk.
